Literature DB >> 19204671

Osiris seals billion-dollar deal with Genzyme for cell therapy.

George S Mack.   

Abstract

Mesh：

Year:  2009        PMID： 19204671     DOI： 10.1038/nbt0209-106

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Genzyme backs Osiris, despite Prochymal flop.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2009-11       Impact factor: 54.908

2.  Baculovirus transduction of mesenchymal stem cells triggers the toll-like receptor 3 pathway.

Authors:  Guan-Yu Chen; Hsiao-Chiao Shiah; Hung-Ju Su; Chi-Yuan Chen; Yung-Jen Chuang; Wen-Hsin Lo; Jie-Len Huang; Ching-Kuang Chuang; Shiaw-Min Hwang; Yu-Chen Hu
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

3.  Challenges in the translation and commercialization of cell therapies.

Authors:  Brittany P Dodson; Aaron D Levine
Journal:  BMC Biotechnol       Date:  2015-08-07       Impact factor: 2.563
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.